Trial
NCT00806572
Treatment With hOKT3gamma1(Ala-Ala) in T1DM
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Immune Tolerance Network (ITN)
Condition
Diabetes Mellitus, Type 1
Intervention
hOKT3gamma1(Ala-Ala)
Why stopped
Adverse events related to drug lot
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-08